Skip to main content

Advertisement

SpringerLink
Log in

Synergistic effect of interleukin-2 and a vaccine of irradiated melanoma cells transfected to secrete staphylococcal enterotoxin A

  • Published:
Clinical & Experimental Metastasis Aims and scope Submit manuscript

Abstract

We have previously reported that immunization of mice with melanoma cells transfected to secrete the superantigen, Staphylococcal enterotoxin A (SEA), increased the production of antibodies to the B700 melanoma antigen, stimulated the production of endogenous interleukin 2 (IL-2), activated the expression of CD4, CD8 and CD25 T cell markers and enhanced NK cell activity. Now we show that immunization of mice with a vaccine of irradiated sea-transfected melanoma cells coupled with IL-2 therapy was even more effective in inhibiting the growth of primary melanoma tumors and the development of lung metastases than was the irradiated melanoma cell vaccine alone or IL-2 alone. The morphological and immunological effectiveness of the therapy was dose-dependent on IL-2.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Newell KA, Ellenhorn JDI, Bruce DS et al. In vivo T cell activation by staphylococcal enterotoxin B prevents outgrowth of a malignant tumor. Proc Natl Acad Sci USA 1991; 88: 1074–8.

    Google Scholar 

  2. Newton DW, Dohlsten M, Olsson C et al. Mutations in the MHC class II binding domains of staphylococcal enterotoxin A differently affect T cell receptor V§ specifically. J Immunol 1996; 157: 3988–94.

    Google Scholar 

  3. Tiedemann RE, Fraser JD. Cross-linking ofMHC class I molecules by staphylococcal enterotoxin A is essential for antigen-presenting cell and T cell activation. J Immunol 1996; 157: 3958–66.

    Google Scholar 

  4. Antonsson P, Wingren AG, Hansson J et al. Functional characterization of the interaction between the superantigen staphylococcal enterotoxin A and the TCR. J. Immunol 1997; 158: 4245–51.

    Google Scholar 

  5. Wen R, Surman S, Blackman MA et al. The conventional CD4+ T cell response to staphylococcal enterotoxin B is modified by its superantigenic activity. Cell Immunol 1997; 176: 166–172.

    Google Scholar 

  6. Lando PA, Hedlund G, Dohlsten M et al. Bacterial superantigens as anti-tumor agents: induction of tumor cytotoxicity in human lymphocytes by staphylococcal enterotoxin A. Cancer Immunol Immunother 1991; 33: 231–7.

    Google Scholar 

  7. Yan, X-J, Li X-Y, Imanishi K et al. Study of activation of murine T cells with bacterial superantigens. J Immunol 1993; 150(9): 3873–81.

    Google Scholar 

  8. Hoiden I, Moller G CD8+ cells are the main producers of IL10 and IFN after superantigen stimulation. Scand J Immunol 1996; 44: 501–5.

    Google Scholar 

  9. Muraille E, Devos S, Thielemans K et al. Costimulation regulates the kinetics of interleukin-2 response to bacterial superantigens. Immunol 1996; 89: 245-9.

    Google Scholar 

  10. Soares LRB, Rivas A, Ruegg C et al. Differential response of CD4+V7+ and CD8+V7-T cells to T cell receptor-dependent signals: CD4+V7 T cells are co-stimulation independent and anti-V7 antibody blocks the induction of anergy by bacterial superantigens. Eur J Immunol 1997; 27: 1413–21.

    Google Scholar 

  11. Boussiotis VA, Freeman GJ, Berezovskaya A et al. Maintenance of human T cell anergy: Blocking of IL-2 gene transcription by activated Rap1. Science 1997; 278: 124–8.

    Google Scholar 

  12. Kuroda K, Yagi J, Imanishi K, et al. Implantation of IL-2-containing osmotic pump prolongs the survival of superantigen-reactive T cells expanded in mice injected with bacterial superantigen. J Immunol 1996; 157: 1422–31.

    Google Scholar 

  13. Belfrage H, Dohlsten M, Hedlund G et al. Prevention of superantigeninduced down-regulation of T cell mediated cytotoxic activity by IL-2 in vivo. Immunology 1997; 90: 183–8.

    Google Scholar 

  14. Shrayer D, Koness J, Maizel A. et al. Induction of interleukin-2, natural killer cell activity and anti-melanoma antibodies resulting from immunization of mice with formalinized extracellular antigens (FECA) of murine melanoma. Melanoma Res 1992; 2(1): 47–56.

    Google Scholar 

  15. Shrayer D, Kouttab N, Maizel A et al. Generation of cytotoxic antibodies to the B16 murine melanoma using a formalinized vaccine. Int J Cancer 1993; 53(4): 696–702.

    Google Scholar 

  16. Shrayer DP, Kouttab N, Hearing VJ et al. Immunization of mice with melanoma cells transfected to secrete the superantigen, staphylococcal enterotoxin A. Cancer Immunol Immunother 1998; 46(1): 7–13.

    Google Scholar 

  17. Shrayer D, Bogaars H, Hearing V. et al. Further characterization of a clinically relevant model of melanoma metastasis and an effective vaccine. Cancer Immunol Immunother 1995; 40: 277-82.

    Google Scholar 

  18. Hearing VJ, Gersten DM, Montague PM et al. Murine melanomaspecific tumor rejection activity elicited by a purified melanomaassociated antigen. J Immunol 1986; 137: (1) 379–84.

    Google Scholar 

  19. Shrayer D, Koness J, Kouttab N et al. Preimmunization of mice with formalinized extracellular antigens of melanoma in combination with IL-2 and surgical resection increased survival and tumor control in metastatic melanoma model. J Surg Oncol 1993; 52: 142–9.

    Google Scholar 

  20. Shrayer DP, Cole B, Hearing VS et al. Immunotherapy of mice with an irradiated melanoma vaccine coupled with interleuken-12. Clin Exp Metastasis 1999; 17: 63–70.

    Google Scholar 

  21. Shrayer DP, Tremaine M, Betley MJ et al. Transfection of B16F10 melanoma cells with staphylococcal enterotoxin A. In Molecular Biology of Cancer. Implications for Prevention and Therapy. Maui, Hawaii, 1995; C-50.

  22. Dranoff G, Jaffee E, Lazenby A et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539.

    Google Scholar 

  23. Fidler IJ, Ananthaswamy HN, Esumi N et al. Correlation of growth capacity of cell in hard agarose with successful transfection by the activated c-Ha-ras oncogene and in vivo proliferative capacity at metastatic sites. Anticancer Res 1991; 11: 17.

    Google Scholar 

  24. Gorelik E, Lay G, Kim M et al. Effects of H-2Kb gene on expression of melanoma-associated antigen and lectin-binding sites on B16 melanoma cells. Cancer Res 1991; 51: 5212.

    Google Scholar 

  25. Porgador, A., Feldman, M, Eisenbach, L. H-2Kb− transfection of B16 melanoma cells results in reduced tumorigenicity and metastatic competence. J Immunogenet 1989; 16: 291.

    Google Scholar 

  26. Southern PJ, Berg P. Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter. J Mol Appl Genet 1982; 1: 327.

    Google Scholar 

  27. Uchiyama A, Hoon DSB, Morisaki T et al. Transfection of interleukin 2 gene into human melanoma cells augments cellular immune response. Cancer Res 1993; 53: 949.

    Google Scholar 

  28. Vile RG, Hart IR In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res 1993; 53: 962.

    Google Scholar 

  29. Shrayer DP, Bogaars H, Hearing VJ et al. Immunization of mice with irradiated melanoma tumor cells transfected to secrete lymphokines and coupled with IL-2 or GM-CSF therapy. J Exp Ther Oncol 1996; 1: 126–33.

    Google Scholar 

  30. Gersten DM, Marchalonis JJ. Demonstration and isolation of murine melanoma-associated antigenic surface proteins. Biochem Biophys Res Commun 1979; 90: 1015–24.

    Google Scholar 

  31. Shrayer D, Koness J, Kouttab N et al. Anti-tumor effects of polyvalent and monovalent vaccines coupled with interleukin 2 in a metastatic melanoma model. Int J Oncol 1994; 4: 1121–7.

    Google Scholar 

  32. Shrayer D, Gersten DH, Koness J et al. B700 antigen as a component of an antimelanoma vaccine: Formalinized extracellular antigens. Pigment Cell Res 1992; 5: 107–12.

    Google Scholar 

  33. Shoemaker RH, Dykes DJ, Plowman J et al. Practical spontaneous metastasis model for in vivo therapeutic studies using a human melanoma. Cancer Res 1991; 51: 2837–41.

    Google Scholar 

  34. Hill LL, Korngold R, Jaworski C et al. Primary and metastatic growth of human melanoma in SCID mice. Proc Am Ass Cancer Res 1991; 1614.

  35. Tomita Y, Montague PM, Hearing VJ Monoclonal antibody production to a B16 melanoma associated antigen. Int J Cancer 1985; 35: 543.

    Google Scholar 

  36. Ariel I.M. Malignant Melanoma. New York: Appleton-Century-Crofts.

  37. Pardoll, D.M. Paracrine cytokine adjuvants in cancer immunotherapy. Ann Rev Immunol 1995; 13: 399–415.

    Google Scholar 

  38. Scmidt W, Maas G, Buschle M et al. Generation of effective cancer vaccines genetically engineered to secrete cytokines using adenovirus-enhanced transfer infection (AVET). Gene 1997; 190: 211–6.

    Google Scholar 

  39. Naito K, Pellis NR, Kahan BD Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen. Cancer Res 1988; 48: 101–8.

    Google Scholar 

  40. Biron CA, Young HA, Kassaian MT Interleukin 2-induced proliferation of murine natural killer cells in vivo. J Exp Med 1990; 171: 173–88.

    Google Scholar 

  41. Lamers CHJ, Gratama JW, Putten WIJ et al. Exogenous interleukin 2 recruits in vitro lymphokine-activated killer activity by in vitro activated lymphocytes. Cancer Res 1991; 51: 2324–8.

    Google Scholar 

  42. Ho S, Hafez GR, Ershler WB The effects of interleukin-2 on bone marrow engrafment in a murine model. Lymphokine Cytokine Res 1991; 10: 185–8.

    Google Scholar 

  43. McLaughlin JP, Schlom J, Kantor JM et al. Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2. Cancer Res 1996; 56: 2361–7.

    Google Scholar 

  44. Shrayer DP, Bogaars Hearing VJ et al. Immunization of mice with irradiated melanoma tumor cells transfected to secrete lymphokines and coupled with IL-2 or GM-CSF therapy. J Exp Ther Oncol 1996; 1: 126–33.

    Google Scholar 

  45. Shrayer DP, Bogaars H, Wolf SF et al. A new model of experimental melanoma for vaccine and lymphokine therapy. Int J Oncol 1998; 13: 361–74.

    Google Scholar 

  46. Kirchner D, Panetta JC Modeling immunotherapy of the tumor – immune interaction. J Math Biol 1998; 37: 235–52.

    Google Scholar 

  47. Iacobelli M, Rohwer F, Shanahan P et al. IL-2-mediated cell cycle progression and inhibition of apoptosis does not require NF-kB or activating protein-activation in primary human T cells. J Immunol 162: 3308.

  48. Hearing VJ, Gersten DM, Montague PM et al. Murine melanomaspecific tumor rejection activity elicited by a purified, melanomaassociated antigen. J Immunol 1986; 137(1): 379–84.

    Google Scholar 

  49. Gersten DM, Moody D, Vieira WD et al. Production of monoclonal antibodies against the B700 murine melanoma antigen and their antimelanoma properties. Biochim Biophys Acta 1992; 1138: 109–14.

    Google Scholar 

  50. Gersten DM, Hearing VJ. Demonstration of B700 cross-reactive antigens on human and other animal melanomas. Pigment Cell Res 1988; 1: 434–38.

    Google Scholar 

  51. Walden TL, Farzaneh NK, Hearing VJ et al. Proteinuria of B700, a 67 kD albumin-like melanoma-specific antigen. Pigm Cell Res 1992; 5: 387–93.

    Google Scholar 

  52. Vlock DR, Hearing VJ, Gersten DM Studies on the immunologic cross-reactivity of the B700 (67 kD) and MAA (66 kD) human melanoma antigen. Pigm Cell Res 1992; 5: 98, 71.

    Google Scholar 

  53. Nguyen QH, Roberts RL, Ank BJ et al. Enhancement of antibodydependent cellular cytotoxicity of neonatal cells by interleukin-2 (IL-2) and IL-12. Clin Diagn Imm 1998; 5(1): 98–104.

    Google Scholar 

  54. Kang C, Sheridan C, Koshland ME A stage-specific enhancer of immunoglobulin J chain gene is induced by interleukin-2. Immunity 1998; 8: 285–95.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Surgery and Pathology, University Medical Group/Roger Williams Medical Center affiliated with Boston University School of Medicine, Providence, Rhode Island, USA

    David P. Schrayer, Nicola Kouttab & Harold J. Wanebo

  2. Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA

    Vincent J. Hearing

Authors
  1. David P. Schrayer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicola Kouttab
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vincent J. Hearing
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Harold J. Wanebo
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schrayer, D.P., Kouttab, N., Hearing, V.J. et al. Synergistic effect of interleukin-2 and a vaccine of irradiated melanoma cells transfected to secrete staphylococcal enterotoxin A. Clin Exp Metastasis 19, 43–53 (2002). https://doi.org/10.1023/A:1013875104326

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1013875104326

Search

Navigation